Dual-energy CT and the chemistry of kidney stones
Renal stone care becomes more precise when anatomy is joined to chemistry. A routine non-contrast CT can locate a calculus, measure it and show obstruction, but most stones have similar brightness. Dual-energy CT adds information by acquiring data at two X-ray energy spectra, allowing software to estimate the material that produced the attenuation and separate uric acid from calcium-bearing stones.
The distinction can change management, but it does not replace clinical assessment. Size, position, obstruction, infection, kidney function and symptoms remain central. A patient may be told that a 6-mm stone is “likely uric acid” and may then be managed conservatively, while a similar calcium stone may require an operation. Composition is one branch of the decision tree, not the trunk.
For Australian practice, technical promise must be balanced against access, cost and communication. DECT is not routine everywhere, and its result is rarely the final word. This article examines what dual-energy CT can characterise, where uncertainty remains, how imaging may influence treatment, and what patients and clinicians should expect along an Australian care pathway.
What dual-energy CT reveals
Conventional CT measures attenuation in Hounsfield units, so a dense calcium stone and a less dense uric acid calculus may look alike. DECT acquires low- and high-energy datasets. Its basis-material decomposition compares how attenuation changes between those spectra, then assigns a likely composition. In practice, the clearest clinical distinction is usually uric acid versus calcium-containing material, although some systems also classify calcium oxalate, calcium phosphate and struvite.
A colour-coded overlay is a visual guide, not a verdict. Small calculi, especially those below roughly 4–6 mm, are harder to characterise because each voxel contains little stone and more noise. Motion, streak artefact, body habitus and scanner vendor can affect results. Dual-energy acquisition may also carry a similar or somewhat higher dose than a conventional study, depending on protocol, so the extra information should justify the exposure and cost.
Turning composition into treatment choices
Urgency comes first. Fever with an obstructed collecting system, kidney injury, uncontrolled pain or inability to pass urine requires urgent hospital care. DECT may identify composition, but it must not delay antibiotics, drainage or other emergency management. In Australian emergency departments, “renal colic” often leads to a non-contrast CT, while a patient with suspected infection may need urological assessment and drainage regardless of stone chemistry.
For a stable patient with an uncomplicated uric acid stone, the result can support a medical pathway. Clinicians may recommend hydration, review dietary and medication factors, and prescribe urinary alkalinisation when appropriate. Repeated imaging can confirm dissolution, and the stone may pass. These decisions depend on symptoms and renal function; a DECT label alone cannot guarantee that treatment will succeed or that follow-up will be easy.
Calcium stones usually require a different discussion. Small asymptomatic stones may be observed with hydration and metabolic review, while larger or troublesome stones may need a procedure. Struvite associated with infection calls for eradication of the infection and complete clearance of the infected obstruction. Retrieved fragments remain valuable for laboratory analysis, confirming composition and guiding recurrence prevention. Good counselling also matters: work on the psychological effects of stuttering highlights how uncertainty, stigma and poorly explained decisions can affect a patient’s confidence.
Evidence, uncertainty and emerging tests
Clinical performance varies with scanner technology, acquisition protocol, stone size and the reference standard used in each study. Results from a centre using one vendor’s material-decomposition system should not be assumed to transfer unchanged to another hospital. Local validation against laboratory analysis of recovered stones provides a practical way to measure accuracy, identify weak categories and determine which predictions should influence treatment.
Molecular testing is also moving forward. Research into microRNA biomarkers in prostate cancer illustrates the wider effort to characterise disease through molecular signatures. No circulating microRNA panel currently replaces DECT for locating stones, quantifying obstruction or distinguishing a treatable uric acid calculus. Imaging and laboratory analysis remain complementary, each answering a different clinical question.
The clinical pathway in Australia
Australian care pathways vary. For non-emergency symptoms, many people first see a GP, who may arrange a kidney-stone CT and refer to a urologist. Acute severe pain commonly leads through an emergency department. A urologist can then decide whether DECT is likely to alter treatment rather than repeating standard CT for every patient. Clear referral language—“uric versus calcium composition, if this will change management”—helps radiology teams target the additional information appropriately.
Public patients generally receive Medicare-funded care through the public hospital system, while private imaging involves a referral, radiology fees and sometimes private health insurance. Whether a private scan attracts a Medicare Benefits Schedule rebate depends on the specific imaging item and clinical circumstances, and DECT can still leave an out-of-pocket gap. Patients should be told to check their policy or obtain an estimate before proceeding. Public waiting lists also influence whether elective characterisation is arranged immediately or folded into a later outpatient review.
Clear documentation supports consistent decisions. Departments can specify when DECT is indicated, which confidence levels are acceptable and how uncertain classifications should be reported. The journal’s sample article provides a useful reference for presenting methods, results and limitations in a structured urological format.
Access, equity and patient communication
Availability is uneven across Australia. Large metropolitan hospitals in Melbourne, Sydney, Brisbane, Perth and Adelaide generally offer the widest range of imaging, while some regional centres have conventional CT but limited dual-energy capability. For patients in northern Queensland, South Australia or the Northern Territory, obtaining the scan may mean travelling to a tertiary centre. Rapid access for infected obstruction or kidney injury must therefore be distinguished from elective assessment intended to guide conservative treatment.
Equity includes clear, culturally safe communication. Aboriginal and Torres Strait Islander patients may need an Aboriginal health practitioner, interpreter or family member involved in the discussion, particularly when several treatment options are being weighed. Imaging reports should translate technical labels into understandable information about stone burden, blockage and likely treatment. National independent coverage from The Tribe Daily can provide context on community priorities and health inequalities that a scan report cannot convey.
Patients also benefit from hearing what DECT cannot establish. Terms such as “likely uric acid” are more informative than a confident colour assignment, while a note that composition is uncertain for a small stone allows an informed conversation about observation, repeat imaging or intervention. Local wording matters: patients often describe wanting “a scan for the kidney stone” or relief from “the blockage,” and clinicians should connect those plain terms with the clinical consequences of the imaging result.
Protocol, reporting and future direction
Reliable use begins with protocol design. Thin-slice non-contrast images remain essential for measuring stone burden and defining anatomy. DECT datasets should be acquired with appropriate kernel reconstruction and quality controls, while motion, artefacts and dose need regular audit. A material-decomposition label should accompany measurements of size, location, hydronephrosis, perinephric stranding and renal function. Prospective outcome studies are needed to show when classification changes management or avoids an intervention.
Claims of benefit should also be tied to patient outcomes. Reviews of long-term outcomes in sacral neuromodulation show why durable function matters more than a single procedural metric. The same principle applies to stone imaging. Machine learning may improve consistency and reduce reading time, but it still requires external validation, interpretable reporting and comparison with pathology before it can guide care routinely.
Use dual-energy CT when its result can change immediate management, report composition with confidence limits, and audit local predictions against recovered-stone analysis. These actions give Australian patients clearer choices while keeping imaging uncertainty visible.